Zacks Investment Research
09 Jul 2026, 19:26 UTC · 2h ago
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
09 Jul 2026, 19:26 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The U.S. regulatory agency has set a target action date of December 3, 2026, for the approval of zanzalintinib in combination with Roche's Tecentriq for metastatic colorectal cancer. — Approval of this key late-stage asset would establish a new commercial growth platform and diversify the company's revenue beyond its flagship therapy.
+0.60The company experienced a pipeline setback regarding the final analysis of overall survival in a specific patient subset (non-liver metastases) in the STELLAR-303 study. — Clinical trial disappointments in late-stage studies create risk and can lead to volatility if the asset's total addressable market is perceived as smaller.
-0.30Exelixis (EXEL) shares have surged 26.8% over the last three months, significantly outperforming its industry and the S&P 500. — Strong price momentum indicates high investor optimism, though it may also signal that recent positive news is already priced in.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
Shares have surged 26.8% and outperformed the sector and S&P 500 due to pipeline momentum.
Positive outlook linked to the potential regulatory approval of a combined treatment with its drug Tecentriq.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
4h ago
